– Celsion Corp shares plunged by more than 80 percent after a
late-stage study of the company’s experimental liver cancer treatment
ThermoDox failed to meet the main goal of increasing patients’ survival
without worsening their cancer.
The stock fell to a low of $1.41 before recovering slightly to trade at $1.46 on heavy volume on the Nasdaq on Thursday.
don’t believe the data will support (marketing) registration in any of
the major markets,” Celsion Chief Executive Michael Tardugno said on a